HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Alert Investors to Sanjay Gupta/CNN Program on Ketamine, Featuring Kadima Neuropsychiatry Institute Founder Dr. David Feifel

Company Overview - HOPE Therapeutics Inc is a development stage healthcare delivery company focused on creating a network of interventional psychiatry clinics offering ketamine transcranial magnetic stimulation (TMS) and other therapies for suicidal depression and related disorders [1] - The company is developing a digital therapeutic-enabled platform to enhance the clinical benefits of NMDA-targeted drug therapy [1] - HOPE Therapeutics is a wholly-owned subsidiary of NRx Pharmaceuticals Inc [5] Key Developments - NRx Pharmaceuticals has initiated filing a New Drug Application for NRX-100 (IV ketamine) for treating suicidal depression based on clinical trial results from US National Institutes of Health and French health authorities data [2] - NRX-100 received Fast Track Designation from the US FDA for treating acute suicidality [2] - HOPE Therapeutics plans to acquire Kadima Neuropsychiatry Institute as its flagship clinic [3][5] - Dr David Feifel, founder of Kadima and a global leader in interventional psychiatry, is expected to join HOPE as Chief Medical Innovation Officer [3][6] Industry Insights - Ketamine treatment requires appropriate psychiatric supervision in controlled settings, as emphasized by Dr Feifel and supported by HOPE Therapeutics [7] - The recent death of Mathew Perry highlights the need for psychiatric centers of excellence providing ketamine and advanced treatments for depression [8] - Dr Feifel plans to bring his successful ketamine treatment methods from Kadima to the HOPE network [8] Parent Company Information - NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing NMDA platform-based therapeutics for central nervous system disorders [9] - The company is developing NRX-101, an FDA-designated Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain [9] - NRx plans to file an NDA for Accelerated Approval of NRX-101 for bipolar depression with suicidality or akathisia [9] - NRX-101 has potential as a non-opioid treatment for chronic pain and complicated UTI [9]